![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, December 18, 2012 9:46:52 AM
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
These are his own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Right now MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
AMBS is only worth $13-14 Million right now.
Versus $250 Million.
Do the math.
And listen to people that know the science like Dr. Rubinfeld who said "I believe that MANF could be one of the biggest successes that I have ever seen". This isn't just some schlub. It's the co-founder of Amgen.
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM